Opendata, web and dolomites

CADISS SIGNED

A medical device for the selective dissection of pathological tissues and fibrosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CADISS project word cloud

Explore the words cloud of the CADISS project. It provides you a very rough idea of what is the project "CADISS" about.

amounting    minimizing    revolutionary    surgeries    tissues    optimize    damage    size    anesthesia    selective    time    repair    despite    chemically    valued    critical    150    dissecting    healthy    undergo    cadiss    weakens    organ    dissection    tearing    saves    rooms    disease    money    international    whereby    tissue    surgery    force    damages    10    health    risks    consisting    remove    2016    combines    separation    surgeon    involve    9m    drug    chemical    million    burden    market    save    30    hospitals    treatable    separated    period    tools    thereby    relying    least    cleavage    countries    expansion    cagr    company    hospital    grow    found    cutting    surgically    surgical    plane    carefully    people    launch    damaged    mesna    reaching    true    surrounding    revenues    diseased    incidence    optimal    adhesion    2025       topical    replace    pioneer    23    risk    reducing    auxin    attributed    global    mechanical    sub    billion    pathological    difficulties    assisted    shorter    either    relapse    patients    space    complications    occupation   

Project "CADISS" data sheet

The following table provides information about the project.

Coordinator
AUXIN SURGERY 

Organization address
address: RUE LOUIS DE GEER 6
city: LOUVAIN LA NEUVE
postcode: 1348
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AUXIN SURGERY BE (LOUVAIN LA NEUVE) coordinator 50˙000.00

Map

 Project objective

Surgery is the art of dissecting tissues in order to repair, remove, or replace a diseased or damaged organ. 30% of the global burden of disease can be attributed to surgically treatable conditions. More than 10% of surgical procedures involve critical dissection steps whereby the pathological tissue is carefully separated from the healthy surrounding tissues. These procedures together have an incidence of 150/100.000 people, amounting for 2 million surgeries per year in developed countries. Despite the importance of selective dissection in surgical procedures, the current tools are sub-optimal because they are all still relying either on tearing force or on non-selective cutting that can damage tissues. Auxin Surgery, a pioneer in novel dissection methods, has found a revolutionary system, CADISS, that combines mechanical force with the topical application of a chemical drug, Mesna that weakens adhesion between tissues thereby facilitating the dissection steps and minimizing the damages to health tissues. CADISS saves time, therefore patients need to undergo anesthesia for shorter period, thereby reducing the risks of complications. Moreover, hospitals save money on the usage of operating rooms and hospital personnel and can optimize the occupation of hospital space. The global general surgery devices market size was valued at over €10 billion in 2016 and is expected to grow at a CAGR of 8.5% by 2025. Chemically assisted dissection can be useful in most surgical procedures consisting in separation of two tissues along a cleavage plane and when at least one of these conditions is true: 1) the risk of relapse is present 2) the risk of side-effects through damage of healthy tissue is present or 3) the risk of facing difficulties for the surgeon is present. CADISS will bring our company to international expansion and growth reaching €23.9M in revenues 3 years after market launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CADISS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CADISS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More